Glucagon Receptor-mediated Extracellular Signal-regulated Kinase 1/2 Phosphorylation in Rat Mesangial Cells: Role of Protein Kinase A and Phospholipase C
Overview
Affiliations
Glucagon, a major insulin counterregulatory hormone, binds to specific Gs protein-coupled receptors to activate glycogenolytic and gluconeogenic pathways, causing blood glucose levels to increase. Inappropriate increases in serum glucagon play a critical role in the development of insulin resistance and target organ damage in type 2 diabetes. We tested the hypotheses that: (1) glucagon induces proliferation of rat glomerular mesangial cells through glucagon receptor-activated phosphorylation of mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 (p-ERK 1/2); and (2) this phosphorylation involves activation of cAMP-dependent protein kinase A (PKA) and phospholipase C (PLC)/[Ca2+]i signaling pathways. In rat mesangial cells, glucagon (1 nM) stimulated [3H]-thymidine incorporation by 96% (P<0.01). This proliferative effect was blocked by the specific glucagon receptor antagonist [Des-His1-Glu9] glucagon (1 micromol/L; P<0.01), a mitogen-activated protein kinase/ERK kinase inhibitor PD98059 (10 micromol/L; P<0.01), a PLC inhibitor U73122 (1 micromol/L; P<0.01), or a PKA inhibitor H-89 (1 micromol/L; P<0.01). The proliferation was associated with a 2-fold increase in p-ERK 1/2 that peaked 5 minutes after glucagon stimulation (P<0.01) and also was blocked by [Des-His1-Glu9] glucagon. Total ERK 1/2 was not affected by glucagon. Pretreating of mesangial cells with U73122 or H89 significantly attenuated ERK 1/2 phosphorylation induced by glucagon. We believe that these are the first data showing that glucagon activates specific receptors to induce ERK 1/2 phosphorylation and thereby increase mesangial cell proliferation and that this effect of glucagon involves both PLC/[Ca2+]i- and cAMP-dependent PKA-activated signaling cascades.
Wang M, Zhang Z, Zhao S, Onodera T, Sun X, Zhu Q Cell Metab. 2024; 36(3):575-597.e7.
PMID: 38237602 PMC: 10932880. DOI: 10.1016/j.cmet.2023.12.024.
Glucagon and Its Receptors in the Mammalian Heart.
Neumann J, Hofmann B, Dhein S, Gergs U Int J Mol Sci. 2023; 24(16).
PMID: 37629010 PMC: 10454195. DOI: 10.3390/ijms241612829.
Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.
Rodgers R Physiol Rep. 2022; 10(9):e15263.
PMID: 35569125 PMC: 9107925. DOI: 10.14814/phy2.15263.
Synthesis and anti-diabetic activity of novel biphenylsulfonamides as glucagon receptor antagonists.
Lee C, Choi H, Park E, Nguyen T, Maeng H, Mee Lee K Chem Biol Drug Des. 2021; 98(5):733-750.
PMID: 34310065 PMC: 9291748. DOI: 10.1111/cbdd.13928.
Huang H, Shen L, Huang H, Zhao L, Xu F, Zhang D Diabetes Metab J. 2021; 45(6):868-879.
PMID: 33752319 PMC: 8640146. DOI: 10.4093/dmj.2020.0149.